Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials

Journal of Medical Virology

Volumn 82, Issue 5, 2010, Pages 768-775

  Fabrizi, O ^a,b   Dixit, Vivek ^b   Messa, Piergiorgio ^a   Martin, Paul ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Dialysis; Drop out; Hepatitis C; Pegylated interferon; Virological response

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

ACUTE ABDOMEN; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; CHOLANGITIS; CHRONIC HEPATITIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DEPRESSION; DIALYSIS; DIARRHEA; DIPLOPIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HEADACHE; HEART DISEASE; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; INFECTION; LIVER FAILURE; META ANALYSIS; MONOTHERAPY; PANCYTOPENIA; PERICARDITIS; PNEUMONIA; SEIZURE; SEPSIS; STROKE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULITIS;

ADULT; ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; TREATMENT OUTCOME; VIRAL LOAD; WITHHOLDING TREATMENT;

HEPATITIS C VIRUS;

EID: 77950973727     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21542     Document Type: Article

References (50)

1. Akhan SC, Kalender B, Ruzgar M. 2008. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection 36:341-344.
2. Amarapurkar DN, Patel ND, Kirpalani AL. 2007. Monotherapy with peginterferon alpha-2b (12 kDa) for chronic hepatitis C infection in patients undergoing haemodialysis. Trop Gastroenterol 28:16-18.
3. Annichiarico BE, Siciliano M. 2004. Pegylated interferon alpha-2b monotherapy for hemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther 20:123-127.
4. Ayaz C, Celen MK, Yuce UN, Geyik MF. 2008. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol 14:255-259. (Pubitemid 351314308)
5. Badalamenti S, Catania A, Lunghi G, Covini G, Bredi E, Brancaccio D, Salvadori M, Como G, Ponticelli C, Graziani G. 2003. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: Only coincidental phenomena? Am J Kid Dis 42:143-150.
6. Barril G, Quiroga JA, Sanz P, Rodriguez-Salvanes F, Selgas R, Carreno V. 2004. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: Impact of permeability and pore size of dialysers. Aliment Pharmacol Ther 20:37-44. (Pubitemid 38938717)
7. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. 2006. Pegylated interferon and ribavirin treatment for hepatitis C in hemodialysed patients. J Viral Hepat 13:316-321.
8. Carbognin SJ, Solomon NM, Yeo FE, Swanson SJ, Bohen EM, Koff JM, Sabnis SG, Abbott KC. 2006. Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: A case report. Am J Transplant 6:1746-1751.
9. Caro P, Nunez A, Delgado R, Dapena F, Amann R. 2007. Good virological response to pegylated interferon alfa monotherapy of chronic hepatitis C infection in hemodialysis patient. Nefrologia 27:77-80.
10. Carriero D, Fabrizi F, Uriel A, Park J, Martin P, Dieterich DT. 2008. Treatment of dialysis patients with chronic hepatitis C using pegylated-interferon and low dose ribavirin. Int J Artif Organs 31:295-302. (Pubitemid 351890659)
11. Casanovas-Taltavull T, Baliellas C, Llobet M, Cruzado JM, Castellote J, Casanova A, Niubo J, Valls C, Serrano T. 2007. Preliminary results of treatmentwith pegylated interferon alpha2a for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant Proc 39:2125-2127.
12. Chan TM, Ho SKN, Tang CSO, Tse KC, Lam MF, Lai KN, Yung S. 2007. Pilot study of pegylated interferon-alpha 2a indialysis patients with chronic hepatitis C virus infection. Nephrology 12:11-17. (Pubitemid 46246544)
13. Covic A, Maftei ID, Mardare NGI, Ionita-Radu F, Totolici C, Tuta L, Golea M, Volovat C, Gusmeth-Tatomir P, Micescu G. 2006. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: Results from a large, multicenter audit. J Nephrol 19:794-801.
14. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986. 7:177-188.
15. Engel M, Malta FM, Gomes MM, Mello JR, Pinho JR, Ono-Sita SK, Carrilho FJ. 2007. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil. BMC Public Health 4:50. (Pubitemid 46662587)
16. Espinosa M, Arenas MD, Aumente MD, Barril G, Buades JM, Aviles B, Carretero D, Alvarez-Lara MA, Carnicer F, Martin-Malo A, Aljama P. 2007. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients. Clin Nephrol 6:366-373.
17. Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Gerosa S, Vinson S, Mousa M, Gitnick G. 1988. Quantitative assessment of HCV load in chronic hemodialysis patients: A cross-sectional survey. Nephron 80:428-433.
18. Fabrizi F, Lunghi G, Ganeshan V, Martin P, Messa P. 2007a. Hepatitis C virus infection and the dialysis patient. Semin Dial 20: 416-422.
19. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. 2007b. The impact of hepatitis C virus infection on survival in dialysis patients: Meta-analysis of observational studies. J Viral Hepat 14:697-703. (Pubitemid 47414935)
20. Fabrizi F, Dixit V, Messa P, Martin P. 2008. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 15:79-88.
21. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. 2005. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 18:52-61. (Pubitemid 40348277)
22. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW. 2003. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol 14:3270-3277.
23. Griveas I, Germanidis G, Visvardis G, Morice Y, Perelson AS, Pawlotsky JM, Papadopolou D. 2007. Acute hepatitis C in patients receiving hemodialysis. Ren Fail 29:731-736. (Pubitemid 47346989)
24. Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V. 2002. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 42:1109-1115.
25. Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. 2009. HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J Clin Gastroenterol 43:477-481.
26. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. 2003. Measuring inconsistencies in meta-analysis. Br Med J 327:557-560.
27. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.2008. Kidney Int 73(Suppl. 109): S1-S99.
28. Kokoglu OF, Ucmak H, Hosoglu S, Cetinkaya A, Kantarceken B, Buyukbese MA, Isik IO. 2006. Efficacy and tolerability of pegylated -interferon alpha-2a inhemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 21:575-580.
29. Lederer S, Zachoval R, Hasholzner U, Schiff H. 2008. Two consecutive episodes of acute hepatitis C with different genotypes in a hemodialysis patient responsive to peg-IFN monotherapy. Clin Nephrol 69:313-316. (Pubitemid 351516279)
30. Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, Hung PH, Liu CJ, Lai MY, Chen JH, Chen PJ, Kao JH, Chen DS. 2008. Pegylated interferon alfa-2a versus standard interferon alfa-2a for treatment-naïve dialysis patients with chronic hepatitis C: A randomised study. Gut 57:525-530.
31. Martin P, Carter D, Fabrizi F, Dixit V, Conrad A, Artinian L, Peacock V, Wilkinson A, Lassman CR, Danovitch G. 2000a. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 69:1479-1484.
32. Martin P, Mitra S, Farrington K, Martin N, Modi MW. 2000b. Pegylated (40 KD) interferon alfa-2a (Pegasys) is unaffected by renal impairment. Hepatology 32:370A [Abstract].
33. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. for the Hepatitis Interventional Group. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492.
34. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. 2004. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 36:1831-1834.
35. Mukherjee S, Gilroy RK, McCashland TM, Schafer DF. 2003. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: A prospective cohort study. Transplant Proc 35:1478-1479.
36. Petitti DB. 2001. Approaches to heterogeneity in meta-analysis. Statist Med 20:3625-3633.
37. Potthoff A, Wiegand J, Luth JB, Wedemeyer H, Manns MP, Tillmann HL. 2005. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis? Clin Nephrol 63:232-235.
38. Poynard T, Conn HO.1985. Theretrieval of randomised clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials 6:271-279.
39. Rampino T, Arbustini E, Gregorini M, Giallini P, Libetta C, Maggio M, Ranghino A, Silini E, Soccio G, Dal Canton A. 1999. Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor. Kidney Int 56:2286-2291.
40. Rendina M, Castellaneta NM, Castellaneta A, Losito A, Schena A, Stallone G, Schena FP, di Leo A, Francavilla A. 2007. The treatment of chronic hepatitis C with peginterferon alpha2a (40 kDa) plus ribavirin in hemodialysed patients awaiting renal transplant. J Hepatol 46:764-768.
41. Rivera M, Gentil MA, Sayago M, Gonzalez-Roncero F, Trigo C, Algarra G, Pereira P, Valdivia MA, Aguilar J. 2005. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc 37:1424-1425.
42. Rostaing L, Chatelut E, Payen JL, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P. 1998. Pharmacokinetics of alpha IFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 9:2344-2348.
43. Russo MW, Goldsweig C, Iacobson M, Brown RS. 2003. Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol 98:1610-1615.
44. Russo MW, Ghalib R, Sigal S, Joshi V. 2006. Randomized trial of pegylated interferon alpha-2b monotherapy in hemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 21:437-443.
45. Schmitz V, Kiessling A, Bahra M, Puhl G, Kahl A, Berg T, Neuhaus R, Neuhaus P, Neumann U. 2007. Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant 12:22-27.
46. Sikole A, Dzekova P, Selja N, Nikolov IG, Zazbun M, Muharemi S, Asani A, Amitov V, Mena S, Grunevska V, Ivanovski L, Polenakovic M. 2008. Treatment of hepatitis C in haemodialysis patients with pegylated interferon alpha2a as monotherapy. Ren Fail 29:961-966.
47. Sporea I, Popescu A, Sirli R, Golea O, Totolici C, Danila M, Vernic C. 2006. Pegylated interferon alpha2a treatment for chronic hepatitis C in patients on chronic hemodialysis. World J Gastroenterol 12:4191-4194.
48. Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burneir M. 2005. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 20:991-993.
49. UcMak H, Kokoglu OF, Hosoglu S, Dogasn E, Sayarlioglu H, Kuzhan N, Isik IO. 2008. Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients. Ren Fail 30:227-232.
50. van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, Tan AC. 2008. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 23:721-725.